Citation only
via OpenAlex
The Role of Plasminogen Activator Inhibitor Type-1 in Fibrosis
Panagiotis Flevaris, Douglas E. Vaughan
Seminars in Thrombosis and Hemostasis · 2016 · ▲ 160 citations
Abstract
Extracellular matrix (ECM) deposition during wound healing is a physiological response to an insult. Wound healing becomes deregulated in the setting of chronic injury or long-standing metabolic disease, leading to the accumulation of ECM components and fibrosis. Matrix protein turnover is determined by the rate of synthesis as well as the rate of proteolytic degradation and clearance by matrix metalloproteinases (MMPs). The persistent activation of interstitial myofibroblasts, coupled with defects in matrix proteolysis, ultimately disrupts tissue architecture and leads to biochemical and mechanical organ dysfunction with eventual organ failure. Plasminogen activator inhibitor type-1 (PAI-1) regulates tissue homeostasis and wound healing by inhibiting plasmin-mediated MMP activation. Multiple reports using models of liver, lung, and kidney fibrosis suggest that PAI-1 deficiency or inhibition of PAI-1 activity attenuates fibrosis. The disinhibition of plasmin-mediated MMP activation leads to collagen degradation and its diminished accumulation, resulting in the reduction of fibrotic matrix deposition in these organs. Paradoxically, homozygous deficiency of PAI-1 promotes age-dependent spontaneous cardiac fibrosis, suggesting a protective role for PAI-1 in the heart. It remains unclear whether PAI-1-deficient cardiac fibroblasts have increased proliferative, migratory, or differentiation capabilities, that allow them to overcome increased plasmin and MMP activity and matrix clearance. In this review, we examine the specific roles of PAI-1 in fibrosis of different organs including the lung, liver, kidney, and cardiovascular system.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1055/s-0036-1586228
- Canonical
- link ↗
- Fetched
- 2026-10-25 MST
Cite this
APA
Flevaris, P., & Vaughan, D.E. (2016). The Role of Plasminogen Activator Inhibitor Type-1 in Fibrosis. <em>Seminars in Thrombosis and Hemostasis</em>. https://doi.org/10.1055/s-0036-1586228
Vancouver
Flevaris P, Vaughan DE. The Role of Plasminogen Activator Inhibitor Type-1 in Fibrosis. Seminars in Thrombosis and Hemostasis. 2016. doi:10.1055/s-0036-1586228.
BibTeX
@article{panagiotis2016TheRol,
title = {The Role of Plasminogen Activator Inhibitor Type-1 in Fibrosis},
author = {Panagiotis Flevaris and Douglas E. Vaughan},
journal = {Seminars in Thrombosis and Hemostasis},
year = {2016},
doi = {10.1055/s-0036-1586228},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Phytotherapy Research 2023
Open access · CC-BY
Extracellular matrix turnover: phytochemicals target and modulate the dual role of matrix metalloproteinases ( MMPs ) in liver fibrosis
Communications Biology 2023
Open access · CC-BY
Macrophage-derived GPNMB trapped by fibrotic extracellular matrix promotes pulmonary fibrosis
Journal of Clinical Investigation 2018
Open access · OA
Resolution of organ fibrosis
Technology and health care : official journal of the European Society for Engineering and Medicine 2026
Citation only
ECM-Targeted and cell-based therapies in musculoskeletal and aging-related disorders: A review.
Aging 2010
Open access · CC-BY
Cellular senescence controls fibrosis in wound healing
Molecular Biomedicine 2025
Open access · CC-BY